Immunogenicity and Safety of a Booster Injection of DTaP-IPV//Hib (Pentaxim) Administered Concomitantly With Tetravalent Dengue Vaccine in Healthy Toddlers Aged 15 to 18 Months in Mexico

Trial Profile

Immunogenicity and Safety of a Booster Injection of DTaP-IPV//Hib (Pentaxim) Administered Concomitantly With Tetravalent Dengue Vaccine in Healthy Toddlers Aged 15 to 18 Months in Mexico

Completed
Phase of Trial: Phase III

Latest Information Update: 06 Jan 2017

At a glance

  • Drugs CYD TDV (Primary) ; Hib-DTaP-poliovirus vaccine; Measles mumps and rubella virus vaccine; Pneumococcal 7-valent CRM197 vaccine conjugate
  • Indications Dengue; Diphtheria; Haemophilus infections; Measles; Mumps; Pertussis; Pneumococcal infections; Poliomyelitis; Rubella; Tetanus
  • Focus Pharmacodynamics
  • Sponsors sanofi pasteur
  • Most Recent Events

    • 06 Jan 2017 Primary endpoint (Antibody response) has been met according to the results published in the Pediatric Infectious Disease Journal.
    • 06 Jan 2017 Results published in the Pediatric Infectious Disease Journal.
    • 09 Jul 2013 Planned End Date changed from 1 Sep 2013 to 1 Aug 2014 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top